Barclays
CLRB icon

Barclays’s Cellectar Biosciences CLRB Stock Holding History

Barclays’s Portfolio CLRB Stock Details CLRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.56K Buy
+561
New +$1.57K ﹤0.01% 4895
2024
Q4 		– Sell
-4,017
Closed -$258K – 5300
2024
Q3 		$258K Sell
4,017
-1,723
-30% -$114K ﹤0.01% 4162
2024
Q2 		$430K Sell
5,740
-5,533
-49% -$531K ﹤0.01% 3130
2024
Q1 		$1.35M Buy
+11,273
New +$1.22M ﹤0.01% 2889
2021
Q2 		– Sell
-1
Closed -$1K – 4891
2021
Q1 		$1K Buy
+1
New +$595 ﹤0.01% 4583

Other funds holding CLRB

CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
SC
Stempoint Capital New York $581M AUM 373.68% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
EAM
Empery Asset Management New York $86.5M AUM
DP
Diadema Partners Morristown, New Jersey $791M AUM 245.83% 1-Year Est. Return

Barclays's CLRB Position: Q2 2026 in Review

Barclays opened a new position in Cellectar Biosciences (CLRB) in Q2 2026: 561 shares worth $1.56K. The stake represents ﹤0.01% of the portfolio and ranks #4895 among its holdings. This is a return to the name: Barclays previously reported a position in CLRB as recently as Q3 2024.

Barclays first reported a position in CLRB in Q1 2021 and has held it in 5 quarters since. The position peaked at $1.35M in Q1 2024. 29 funds tracked by Wall St. Rank hold CLRB as of Q2 2026.

  • Barclays held 561 shares of Cellectar Biosciences worth $1.56K as of Q2 2026.
  • Cellectar Biosciences was a new Barclays position in Q2 2026.
  • Cellectar Biosciences made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4895 holding.
  • Barclays first reported a position in Cellectar Biosciences in Q1 2021 and has held it in 5 quarters since.
  • Barclays's Cellectar Biosciences position peaked at $1.35M in Q1 2024.
  • 29 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.